DE2552473A1 - Zerfallmittel fuer tabletten - Google Patents
Zerfallmittel fuer tablettenInfo
- Publication number
- DE2552473A1 DE2552473A1 DE19752552473 DE2552473A DE2552473A1 DE 2552473 A1 DE2552473 A1 DE 2552473A1 DE 19752552473 DE19752552473 DE 19752552473 DE 2552473 A DE2552473 A DE 2552473A DE 2552473 A1 DE2552473 A1 DE 2552473A1
- Authority
- DE
- Germany
- Prior art keywords
- tubes
- tablets
- tablet
- cellulose
- disintegrant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000007884 disintegrant Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 230000004323 axial length Effects 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229920006184 cellulose methylcellulose Polymers 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 84
- 239000000203 mixture Substances 0.000 description 13
- 239000008187 granular material Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000012510 hollow fiber Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- -1 gastric juice Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000011162 core material Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960004482 quinidine sulfate Drugs 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- UUIVKBHZENILKB-UHFFFAOYSA-N 2,2-dibromo-2-cyanoacetamide Chemical compound NC(=O)C(Br)(Br)C#N UUIVKBHZENILKB-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000010035 extrusion spinning Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010338 mechanical breakdown Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005371 permeation separation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000012503 pharmacopoeial method Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/508,025 US3951821A (en) | 1972-07-14 | 1974-09-20 | Disintegrating agent for tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2552473A1 true DE2552473A1 (de) | 1977-05-26 |
Family
ID=24021073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752552473 Withdrawn DE2552473A1 (de) | 1974-09-20 | 1975-11-22 | Zerfallmittel fuer tabletten |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE836041A (enExample) |
| DE (1) | DE2552473A1 (enExample) |
| FR (1) | FR2333495A1 (enExample) |
| GB (1) | GB1485659A (enExample) |
| NL (1) | NL7513790A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112250505A (zh) * | 2020-10-30 | 2021-01-22 | 云南云天化红磷化工有限公司 | 一种速溶粒状磷铵用崩解剂及其制备方法和应用 |
-
1975
- 1975-11-22 DE DE19752552473 patent/DE2552473A1/de not_active Withdrawn
- 1975-11-26 NL NL7513790A patent/NL7513790A/xx not_active Application Discontinuation
- 1975-11-27 GB GB4873375A patent/GB1485659A/en not_active Expired
- 1975-11-27 BE BE162256A patent/BE836041A/xx unknown
- 1975-12-01 FR FR7536748A patent/FR2333495A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2333495B1 (enExample) | 1978-11-10 |
| FR2333495A1 (fr) | 1977-07-01 |
| BE836041A (fr) | 1976-05-28 |
| NL7513790A (nl) | 1977-05-31 |
| GB1485659A (en) | 1977-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69125619T2 (de) | Arzneimittel mit kontrollierter wirkstoffabgabe | |
| US3951821A (en) | Disintegrating agent for tablets | |
| DE69421263T2 (de) | Verfahren zur Herstellung osmosisgesteuerter Tabletten ohne Verwendung von chlorierten Kohlenwasserstoffen | |
| DE68906488T2 (de) | Verwendung von asymmetrischen membranen in abgabevorrichtungen. | |
| DE1258548C2 (de) | Verfahren zur Herstellung von Arzneimitteltabletten unter Verwendung von Kunstharzen als die Wirkstoffabgabe verzoegernde Einbettungsmassen | |
| AT396329B (de) | Pharmazeutische granulate und verfahren zu ihrer herstellung | |
| DE69006365T2 (de) | Unbeschichtete pharmazeutische reaktionstablette. | |
| DE60206078T2 (de) | Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes | |
| DE2525061C2 (de) | Formkörper zur Abgabe eines Wirkstoffs und Verfahren zu dessen Herstellung | |
| AT402689B (de) | Dosierungsform für die behandlung kardiovaskulärererkrankungen | |
| DE69208299T2 (de) | Feste Arzneizubereitungen zur oralen Verabreichung mit verlängerter Magenverweilzeit | |
| DE3486409T2 (de) | Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs. | |
| AT397180B (de) | Vorrichtung zur kontrollierten abgabe eines wirkstoffes | |
| DE69924710T2 (de) | Pharmazeutische zubereitung zur anwendung in der antiasthmatherapie | |
| DE1093050B (de) | Verfahren zur Herstellung einer Penicillintablette mit verlaengerter Wirkung | |
| DE4406424A1 (de) | Expandierbare Arzneiformen | |
| DE3613454A1 (de) | Arzneimittelabgabevorrichtung | |
| DE3509410A1 (de) | Abgabesystem zur freisetzung eines wirkstoffs | |
| CH671696A5 (enExample) | ||
| CH690955A5 (de) | Oxybutynin umfassende Arzneiform. | |
| DE69813602T2 (de) | Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe | |
| EP0208971A2 (de) | Feste Arzneimittelformen zur peroralen Anwendung enthaltend 9-Deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9S)-erythromycin und Verfahren zu ihrer Herstellung | |
| CH636276A5 (de) | Durch osmose betaetigbare abgabevorrichtung. | |
| DD263231A5 (de) | Verfahren zur herstellung eines festen praeparates mit verzoegerter abgabe eines wirkstoffes | |
| DE19961897A1 (de) | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |